1. Understanding the nature of melasma and distinguishing it from other hyperpigmentation

Melasma is one of the most challenging and persistent acquired skin pigmentation disorders, appearing as symmetrical, light to dark brown and gray macules and plaques, usually on sun-exposed areas such as the forehead, cheeks, bridge of the nose, and upper lip. Melasma treatment has profound structural differences from the removal of common age spots (solar lentigo) or post-inflammatory hyperpigmentation (PIH). In melasma, we are not dealing with a simple accumulation of melanin in the keratinocytes; rather, there is an altered tissue network of hyperactive melanocytes, abnormal new blood vessels, solar elastosis, and a disrupted basement membrane at the root of the disease.

In comparison, age spots generally have well-defined, limited margins and respond more quickly to exfoliative interventions, while melasma, due to its extreme cellular excitability, has a high likelihood of recurrence or reactive darkening (rebound) with aggressive approaches.

2. Pathophysiology, role of melanocytes and triggering factors

The pathology of melasma is no longer considered a purely epidermal disorder, but rather a disorder resulting from the interaction of different layers of the skin and local photoaging. Several biological axes are involved in the exacerbation of this condition:

3. Clinical evaluation and determination of pigmentation depth

Before choosing any treatment path, it is necessary to assess the depth of involvement using Wood's lamp or specialized dermatoscopy. The classification of clinical patterns is generally divided into three main categories:

• Epidermal melasma: Pigmentation is located in the superficial layers of the epidermis. Lesions appear darker under Wood's light, have sharper edges, and respond best and most quickly to topical medications.
• Dermal melasma: Pigmentation is caused by phagocytosis of melanin by macrophages (melanophages) in the papillary and reticular layers of the dermis. Contrast is not enhanced under Wood's light and the lesions are grayish in color. This type requires long-term and combined treatments.
• Mixed melasma: The most common clinical scenario in which pigmentation is simultaneously extended to both the epidermis and dermis.

4. First-line treatment: specialized topical formulations and molecular synergy

The foundation of treatment is provided by topical interventions that inhibit the tyrosinase and melanosome transport enzymatic pathways. The gold standard formulations and non-hydroquinone alternatives are categorized as follows:

Kligman's Formulation

A combination of hydroquinone (usually 2 to 4 percent), tretinoin (0.025 to 0.05 percent), and a mild corticosteroid (such as fluocinolone acetonide 0.01 percent). In this combination:

• Hydroquinone: Inhibits the enzyme tyrosinase and stops the production of melanin.
• Tretinoin: Increases epidermal renewal, accelerates pigment removal, and doubles the penetration of hydroquinone.
• Corticosteroid: Neutralizes the inflammation and irritation caused by the other two drugs and is itself a mild inhibitor of melanogenesis.

Novel non-hydroquinone inhibitors

For the maintenance phase or in people with extremely sensitive skin, the following options have the highest level of scientific evidence:

• Azelaic acid (15-20%): Selective inhibitor of tyrosinase in abnormal and hyperactive melanocytes without negatively affecting normal cells; with strong anti-inflammatory properties.
• Topical tranexamic acid (3 to 5%): Reduces the release of arachidonic acid and prostaglandins and attenuates signals between keratinocytes and melanocytes.
• Kojic acid and arbutin: Enzymatic inhibition of tyrosinase by chelating copper ions in the enzyme's active site.
• Niacinamide (2-5%): A definitive inhibitor of the transfer of melanosomes from melanocytes to adjacent keratinocytes without cellular damage.
• Thiamidol: A highly specific and safe human tyrosinase inhibitor with sustained efficacy in long-term use.

5. Systemic approaches: the role of oral tranexamic acid

One of the most important advances in dermatology in the management of recurrent and refractory melasma is the introduction of oral tranexamic acid into treatment protocols. As a synthetic lysine analogue, this drug inhibits plasminogen and reduces plasmin formation, preventing the secretion of fibroblast growth factors and prostaglandins, and simultaneously suppressing both vascular factors and pigmentation.

• Standard therapeutic dose: Much lower than for hemostatic indications; usually 250 mg twice daily for 8-12 week courses.
• Contraindications: History of venous or arterial thromboembolism, coagulation disorders, concomitant use with prothrombotic drugs, and severe renal failure. Family history screening is mandatory before prescribing.

6. Advanced Medical Interventions: Comparison of Clinical Methods

In patients who have responded partially to conservative treatments, the use of clinical methods can accelerate the clearance of the layers, provided that the principle of caution and prevention of thermal or physical irritation is observed.

7. Light protection: Beyond ultraviolet (UV) rays

Strong evidence has shown that, in addition to UVB and UVA, a broad spectrum of high-energy visible light (HEV or Blue Light) , emitted by both the sun and digital screens, has the power to stimulate melanocytes in a deep and long-lasting manner. Visible light-induced pigmentation is more persistent than UV radiation in people with wheatish and green skin phototypes (Fitzpatrick types 3-5).

• Iron Oxides: Conventional colorless sunscreens are not effective at blocking visible light. Tinted sunscreens containing iron oxide are the only proven protective barrier against blue and visible light.
• Physical reflectance spectrum: Micronized zinc oxide and titanium dioxide are essential to provide broad physical coverage.
• Usage rule: Reapply every two to three hours during all daylight hours, regardless of whether you are indoors or the weather is cloudy.

8. Comprehensive protocol for maintenance, lifestyle and prevention of disease recurrence

Melasma is a lifelong disorder with a chronic structure, and no treatment guarantees that it will not return permanently without care. The real success for the doctor and the patient comes in the post-recovery phase: